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Purpose or Objective: Acute urinary unwished effects of 
pelvic irradiation may impact on quality of life of patients 
undergoing radiation therapy on the pelvis. Neoplasms such 
endometrial, cervical, rectal, and anal cancer requires 
irradiation of relevant pelvic volumes. In this study we tested 
Cystoman, a dietary integrator of D-mannosium, cranberry 
and vitamin C, as prophylactic therapy for the development 
of acute urinary side effects. 
 
Material and Methods: Fifty five patients undergoing pelvic 
irradiation were randomly assigned to take 2 tablets/day of 
Cystomann or not from the beginning of radiation therapy. 
Radiation therapy consisted of 45 - 50.4 Gy on the pelvis 
given by 1.8 Gy daily fractions with 3D conformal radiation 
therapy. The patients were weekly checked for urinary 
symptoms. Urine colture was performed before and after the 
treatment. 
 
Results: Between November 2014 and September 2015, 55 
consecutive patients were enrolled in the study. Median age 
was 65 year, 11 were affected by cervical cancer, 9 
endometrial, 31 rectal, and 4 anal cancer. Twenty two 
patients were treated preoperatively and 33 postoperatively. 
Urinary toxicity appeared at the second week in 3/28 
patients in Cystoman group and 11/27 in the control group 
(p=0,02). However by the end of the treatment 8/28 and 
13/27 patients had urinary toxicity in the Cystoman and 
control group, respectively (p=0.1). 
 
Conclusion: Our study suggests that Cystomann delays the 
radio-induced acute urinary toxicity presentation and could 
ameliorate the toxicity profile of the pelvic irradiation. 
 
Electronic Poster: Clinical track: Skin cancer / malignant 
melanoma  
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Purpose or Objective: Description of three cases of total 
skin irradiation for cutaneous T-cell lymphoma using helical 
TomoTherapy (Accuray, Sunnyvale, CA). 
 
Material and Methods: In 2015, three patients with 
refractory T-cell lymphoma underwent total skin irradiation 
using invers-planned helical tomotherapy. The first case was 
a 25-year-old man diagnosed as mycosis fungoides with 
multiple tumors occurring on the extremities, face, and 
trunk. The second case was a 73-year-old woman diagnosed 
as primary cutaneous gamma delta T-cell lymphoma. She had 
received 24 Gy of irradiation in 12 fractions with total skin 
electron beam irradiation technique 10 years ago, and some 
parts of her skin were irradiated with 24 Gy in 12 fractions 
with local electron beam irradiation within 3 years. The third 
case was a 52-year-old man diagnosed as mycosis fungoides. 
No bolus was added around the body. Because of the long 
length of treatment of the body in TomoTherapy, treatments 
were delivered to three parts of the body (trunk, head and 
neck, and legs). Irradiation was not performed in two or 
three parts on the same day. Each plan was generated with a 
prescription dose of 10 Gy in 10 fractions. The planning 
target volume (PTV) was the body surface with 5mm margins 
of internal and external lesions of the skin. The third patient 
had several swelling lymph nodes, so the PTV was the body 
surface and swelled lymph nodes with their margins. 
 
Results: TomoTherapy technique was created that enabled 
delivery of the prescription dose to PTV with a relatively 
sharp drop-off of dose at depth. The calculated mean doses 
for the organs at risk were 1.96, 2.08, 2.12, 2.19, and 2.27 
Gy for the lung, heart, liver, kidneys, and bones, 
respectively. Using the couch-indexed Vac-Lok cushion and 
head mask, inter- and intra-fractional patients motions were 
minimized. All three patients experienced edemas of fingers 
and toes, and lost much of their hair. Myelosuppression 
occurred in two of the three patients. Because of grade 4 
myelosuppression, the second patient who was treated total 
skin electron beam irradiation 10 years ago, was treated with 
blood transfusion during the treatment. All tumors were 
reduced during and after the treatment. 
 
Conclusion: Using the TomoTherapy technique in total skin 
irradiation, we were able to achieve good coverage of the 
PTV and good sparing of organs at risk, including the bones. 
This treatment method, including the prescription dose and 
treatment duration, will be needed further research. 
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Purpose or Objective: After more than 30 years, Ipilimumab 
was the first agent which showed a survival benefit for the 
treatment of metastatic melanoma. However, only about the 
20% of patients have a long-term survival benefit. The 
combination of ipilimumab with other therapies might 
improve its efficacy. Abscopal effect refers to a regression of 
metastatic lesions distant from the primary site of 
radiotherapy (RT). This systemic response is observed in 
patients who received ipilimumab. Here we reported the 
outcomes from patients treated in the ipilimumab Italian 
expanded access program (EAP) who received RT after 
ipilimumab progression. 
 
Material and Methods: Patients with advanced melanoma 
who had received RT after ipilimumab progression were 
eligible for analysis. Radiotherapy was available upon 
physician request for patients who failed ipilimumab therapy 
and for whom no other therapeutic options were available. 
 
Results: 21 out of 95 patients treated with ipilimumab in the 
Italian EAP were eligible for the analysis. The median age 
was of 58 years (range 21-77); the progression free survival 
(PFS) from ipilimumab treatment was 4 months (range 3-6), 
while the time from the end of treatment with ipilimumab 
and RT was of 5 months (range 4-8). RT was performed on 
brain in 13 patients: 8 were treated with whole-brain RT and 
5 patients with stereotactic RT. Other RT treatment included 
bone, metastatic distant lymph nodes, sub-cutaneous 
metastasis, spinal cord metastatis. The median doses was 30 
Gy (range 30-50). A local response to RT was detected in 13 
patients while 8 patients did not show any local regression. 
The abscopal response has been detected in 11/21 patients: 
in details, we observed 9 abscopal partial response , 2 
abscopal stable disease , and 10 progression . The median of 
occurrence of the abscopal response was of 1 month (range 
1-4). The median overall survival (OS) for all the 21 patients 
was of 13 months (range 6-26). The median OS for patients 
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with and without abscopal responses was respectively of 22.4 
months (range 2,5-50,3) and 8,3 months (range 7,6-9.0). 11 
out of 13 patients with local response showed an abscopal 
effect. 
 
Conclusion: The RT after ipilimumab treatment may be an 
option for further potentiate its effect. Local response to RT 
might be predictive for the abscopal response and outcome. 
Further studies are warranted in this field to better 
understand and define the role of RT in combination or 
sequencing with ipilimumab treatment. 
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Purpose or Objective: The aim of this study was to analyze 
differences in radiological responses of melanoma brain 
metastases after Gamma Knife radiosurgery and their 
correlation with patient survival. 
 
Material and Methods: We retrospectively analyzed 78 
patients treated with Gamma Knife radiosurgery for 
melanoma brain metastases between 2009 and 2015 in the 
Radiosurgical centre (Saint-Petersburg, Russia) and subjected 
to follow-up MRI examinations. Patients receiving BRAF 
inhibitor therapy or ipilimumab were not included in the 
study. The study group consisted of 39 men and 39 women 
with a mean age of 52 years. The median KPS was 80 %. 
According to RPA, 14 patients were in Class I, 61 patients in 
Class II, and 3 patients in Class III. Most of the patients 
presented with multiple brain metastases (87 %). 
Radiosurgery was performed with Gamma Knife 4C and 
Perfection units; the mean dose delivered to the tumor 
margin was 20 Gy at 50 % isodose. After treatment, the 
patients underwent control MRI examination with standard 
protocols (2 mm T2 and 1 mm T1 with double contrast 
enhancement) at 8 weeks and at regular 3-month intervals 
thereafter. MR images were analyzed with Gamma Plan 
software. Volumetric measurements of metastases on pre- 
and post-treatment images were performed in order to 
determine different types of radiological response. We 
divided the patients into groups according to the type of 
radiological response and compared Kaplan-Meier survival 
curves in these groups with the long-rank test. 
 
Results: We found that patients with melanoma brain 
metastases had different radiological reactions to Gamma 
Knife radiosurgery. We distinguished several types of 
radiation response: sustained decrease in tumor volume, 
prolonged stabilization of tumor volume, transient increase in 
tumor volume due to intratumoral bleeding with subsequent 
decrease in tumor size, transient increase in tumor volume 
due to radiation-induced necrosis followed by tumor 
shrinkage. Statistical analysis revealed that a rapid decrease 
in tumor volume was associated with poor prognosis. Median 
overall survival of this group of patients was about two times 
less compared with patients whose radiation response 
developed slowly after the first 2 months of radiosurgery (p < 
0.0001). Stratification to RPA classes revealed that patients 
with a rapid response have poorer survival prognosis than 
those with a slow response in the corresponding RPA classes. 
 
Conclusion: Melanoma brain metastases showed different 
radiological responses to radiosurgery. Rapid shrinkage of 
brain metastases is associated with poor survival, which may 
indicate more aggressive biological behavior of this tumor 
subtype. Different radiation sensitivity of melanoma brain 
metastases to Gamma Knife radiosurgery may be associated 
with molecular characteristics of cell subpopulations, which 
determine biological tumor behavior and affect patient 
prognosis. 
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Purpose or Objective: Adult T-cell leukemia–lymphoma 
(ATLL) is a rare disease and a peripheral T-cell malignancy 
associated with human T-cell lymphotropic virus type I 
(HTLV-1) infection. ATLL treatment is based on 
subclassification, and intensive multidrug chemotherapy 
regimens are often used for aggressive subtypes. However, 
disease progression occurs in most of patients. There are only 
a few reports for the radiotherapy in patients with ATLL. 
Therefore, the role of radiotherapy for ATLL is not well 
investigated even for the palliation. The purpose of this study 
was to evaluate the efficacy and toxicity for the radiotherapy 
in patients with ATLL. 
 
Material and Methods: Between April 1983 to October 2013, 
44 patients with 205 ATLL tumor lesions were treated with 
radiotherapy at our institution. Sites of tumor lesions were as 
follows; 184 lesions were in the skin, 13 lesions in the lymph 
nodes, 6 lesions in the central nerves system, and 2 lesions in 
the bone. Acute type on ATLL subtypes was seen in 8 
patients, chronic type in 7 patients, lymphoma type in 10 
patients, smoldering type in 15 patients and others in 4 
patients. Median total dose of radiotherapy was 29Gy (range, 
2-60Gy), and the median fractionated dose was 3Gy (range, 
1-7Gy). For the skin tumor lesions, 45Gy in 15 fractions was 
selected in 33 lesions, 30Gy in10 fractions in 38 lesions, 28Gy 
in 4 fractions in 21 lesions and 20Gy in 5 fractions in 19 
lesions and others in 73 lesions. Only 4 of 44 patients were 
treated with total skin irradiation, and the remaining 40 
patients received conventional radiotherapy for local tumor. 
Efficacy and toxicity of the radiotherapy for ATLL were 
retrospectively evaluated, and the predictors of a long-term 
survival were analyzed. 
 
Results: The median follow-up period was 206 days. 
Objective tumor response rates were 98%. Four of 6 tumor 
lesions with stable disease or progressive disease on 
objective tumor response were associated with aggressive 
subtypes or tumor sites of the central nerves system. In-field 
recurrence after radiotherapy was recognized in 3 (2%) 
lesions. Two-year and 5-year overall survival rates were 76% 
and 44%, respectively. Median overall survival time in 
patients with indolent subtypes (chronic or smoldering type) 
of ATLL was 23 months, while that in patients with aggressive 
subtypes (acute or lymphoma type) was 6 months, and the 
difference was significant. Acute toxicities of Grade 2 
dermatitis were seen in 3 patients. Acute toxicity of Grades 
3–5 was not observed. Late toxicity of ≥Grade 2 was also not 
recognized. 
 
Conclusion: Radiotherapy for ATLL was mainly used for the 
skin lesion and well tolerated, and could achieve excellent 
local tumor control without inducing severe toxicity. 
Radiotherapy should be selected to improve the quality of 
life, and be incorporated into combined modality therapy for 
ATLL. 
 
EP-1395  
Choroidal melanoma: is radiosurgery more efficient? 
L. Larrea
1Hospital NISA Virgen del Consuelo, Radiation Oncology 
Department, Valencia, Spain 
1, E. Lopez1, P. Antonini1, V. Gonzalez1, M. Baños2, 
J. Bea2, M. Garcia2, T. Sanchez-Minguet3, J. Tomas3 
2Hospital NISA Virgen del Consuelo, Physics Department, 
Valencia, Spain 
3Hospital NISA Virgen del Consuelo, Ophtalmology 
Department, Valencia, Spain 
 
